35 Therapy with the immunomodulatory agent pomalidomide does not lead to changes in HIV-1 viral populations in vivo

Affiliations

S.A. Watters: University College London, Division of Infection and Immunity, London, United Kingdom; National Institutes of Health, NCI, HIV Dynamics and Replication Program, Frederick, United States
M.N. Polizzotto: University New South Wales, Kirby Institute for Infection and Immunity, Sydney, Australia
W. Shao: Leidos Biomedical Research Inc, Advanced Biomedical Computing Centre, Frederick National Laboratory, Frederick, United States
R. Gorelick: Leidos Biomedical Research Inc, AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, United States
E.M. Anderson: National Institutes of Health, NCI, HIV Dynamics and Replication Program, Frederick, United States
I. Sereti: National Institutes of Health, NIAID, HIV Pathogenesis Section, Laboratory of Immunoregulation, Bethesda, United States
K. Aleman: National Institutes of Health, NCI, HIV and AIDS Malignancy Branch, Bethesda, United States
L. Kouyoudjian: Leidos Biomedical Research Inc, Clinical Research Directorate/ Clinical Monitoring Research Program, NCI at Frederick, Frederick, United States
J.B. Zeldis: Celgene Corp, Summit, United States
T. Uldrick: National Institutes of Health, NCI, HIV and AIDS Malignancy Branch, Bethesda, United States
R. Yarchoan: National Institutes of Health, NCI, HIV and AIDS Malignancy Branch, Bethesda, United States
F. Maldarelli: National Institutes of Health, NCI, HIV Dynamics and Replication Program, Frederick, United States

Abstract

No abstracts available.